Evofem Biosciences, Inc.

Good afternoon, and welcome to EvoFem's Biosciences second quarter 2021 results call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you'll need to press star 1 on your telephone. Please be advised that today's conference is being recorded. I would now like to turn the call over to EvoFem's Vice President of Investor Relations, Amy Raskoff.

Thank you, and good afternoon, everyone. If you haven't done so already, I encourage you to access the second quarter of 2021 presentation and the press release we issued earlier today, both of which are at evofem.com under the Investors tab. Before we begin, I would like to remind you that remarks on this call will contain forward-looking statements, which are made only as of today, August 11, 2021. For a more detailed description of important risk factors that could cause our actual results to differ materially, please refer to our annual report on Form 10-K and our most recent file, 10-Q. With that, I'll turn the call over to Sandra Pelletier, EvoFem's CEO. Thank you, Amy, and thanks, everyone, for joining us today.

FFM delivered strong and sustainable growth in the second quarter of 2021. This includes 47% growth in Phexie prescriptions and 65% growth in units dispensed. And it also includes a 52% increase in the number of healthcare providers prescribing Phexie. We achieved this despite an ongoing and ever-changing pandemic and a time when many companies bemoaned the impact of COVID on their results, we are delivering and we are growing. The measure of a company's choices in people, strategy, and ability to execute is often best seen in times of crisis. It's much easier to perform when doctors' offices are open, when patients are not on lockdown, and when the overall tone of life is more positive. But what you're going to hear today is that we are delivering on our promise of breaking the hormone glass ceiling, regardless of obstacles. Edelman is proving the contraceptive market was ready for innovation. The birth control category has been dominated by hormones for decades, but there is a demand for a non-hormonal choice without the serious side effects that many women cannot tolerate. There are also the invisible side effects that many women feel just make them not quite like themselves. The feelings that make them worry whether something more serious is happening to their bodies because they take a hormonal medication every day that they don't even need. The demand is there as evidence by our continued growth. We look to harness that movement and accelerate our growth by launching a robust national brand awareness campaign featuring an Emmy award-winning celebrity in early September that will break conventions and will connect with women in new and meaningful ways. I'll discuss this and other ongoing initiatives after our CSO, Jay Files, reviews the financial results and Russ Behrends, our Chief Commercial Officer, discusses veximetrics and reimbursement.